Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at ...

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...

The United States Food and Drug Administration (FDA) has approved Lenacapavir (LEN), a long-acting injectable antiretroviral hailed as a breakthrough in HIV prevention. Experts in India have welcomed ...

While Gilead Sciences' HIV prevention drug lenacapavir got approved by the US Food and Drug Administration (FDA), its made- ...

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...